{"title":"Letter to the editor: Enhancing the clinical utility of a ten-gene prognostic signature for HCC.","authors":"Weiyi Jiang, Jinkai Feng, Shuqun Cheng","doi":"10.1016/j.aohep.2025.102130","DOIUrl":"10.1016/j.aohep.2025.102130","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102130"},"PeriodicalIF":4.4,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Re-evaluating the survival benefit of adding camrelizumab to TACE plus tyrosine-kinase inhibitors in unresectable hepatocellular carcinoma: the undervalued influence of TACE frequency.","authors":"Longshuang Wang, Jian Zhang, Jianfei Liu","doi":"10.1016/j.aohep.2025.102126","DOIUrl":"10.1016/j.aohep.2025.102126","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102126"},"PeriodicalIF":4.4,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145184535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nahum Méndez-Sánchez, Mariana M Ramírez-Mejía, Carlos Cortez-Hernández, Elianee M Tovar-Bojorquez, Raúl Contreras-Omaña, Juan D Monsiváis-Morales, Jacqueline Cordova-Gallardo, Mauricio Castillo-Barradas, Nubia Guzmán-Rodríguez, María S González-Huezo, Adrian Sandez-Araiza, Eira Cerda-Reyes, Stefanny Cornejo-Hernandez, Beatriz Barranco-Fragoso, Ana D Cano-Contreras, José M Remes-Troche, Fatima Higuera-de-la-Tijera, José L Pérez-Hernández, Norberto Chávez-Tapia, Francisco J Valentin-Cortez, Iaarah Montalvo-Gordon, Rubén R Lozano-Salazar, Montserrat Sabanes-Hernández, Itziar Borbolla-Schega, Heriberto Rodríguez-Hernández
{"title":"Epidemiology and etiologic trends of hepatocellular carcinoma in cirrhotic patients in Mexico: a multicenter retrospective study (2018-2024).","authors":"Nahum Méndez-Sánchez, Mariana M Ramírez-Mejía, Carlos Cortez-Hernández, Elianee M Tovar-Bojorquez, Raúl Contreras-Omaña, Juan D Monsiváis-Morales, Jacqueline Cordova-Gallardo, Mauricio Castillo-Barradas, Nubia Guzmán-Rodríguez, María S González-Huezo, Adrian Sandez-Araiza, Eira Cerda-Reyes, Stefanny Cornejo-Hernandez, Beatriz Barranco-Fragoso, Ana D Cano-Contreras, José M Remes-Troche, Fatima Higuera-de-la-Tijera, José L Pérez-Hernández, Norberto Chávez-Tapia, Francisco J Valentin-Cortez, Iaarah Montalvo-Gordon, Rubén R Lozano-Salazar, Montserrat Sabanes-Hernández, Itziar Borbolla-Schega, Heriberto Rodríguez-Hernández","doi":"10.1016/j.aohep.2025.102131","DOIUrl":"10.1016/j.aohep.2025.102131","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Hepatocellular carcinoma (HCC) represents a major complication of chronic liver disease and an emerging public health challenge in Mexico. As the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to increase, a comprehensive understanding of the current epidemiological landscape of HCC has become increasingly important. This study aims to describe the epidemiologic features and etiologic distribution of HCC in patients with cirrhosis in Mexico using multicenter data collected from 2018 to 2024.</p><p><strong>Materials and methods: </strong>We conducted a multicenter retrospective study of 2182 patients with cirrhosis diagnosed between 2018 and 2024 across 13 tertiary care hospitals in northern, central, and southern Mexico. HCC was identified using standardized imaging and/or histological criteria. Data on demographics, cirrhosis etiology and clinical characteristics were collected.</p><p><strong>Results: </strong>Among 2182 patients with cirrhosis (mean age 61 ± 12 years; 53.8 % female), 8.8 % (n = 194) developed HCC. Prevalence was higher in women (55.1 %) and in older adults, with 78.3 % of HCC cases occurring in individuals aged ≥60 years. In women, HCC peaked between ages 70-79, while in men it peaked between 60 and 69 years. Regional differences were observed, with the highest prevalence in central Mexico (10.4 %) and the lowest in the south (3.8 %) (p < 0.001). MASLD was the leading etiology (39.1 %), followed by HCV (33.0 %) and ALD (18.6 %).</p><p><strong>Conclusions: </strong>These findings highlight the growing impact of MASLD as the leading cause of HCC in patients with cirrhosis in Mexico, with notable age, sex and regional disparities. Understanding these patterns is essential to inform targeted prevention and early detection strategies.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102131"},"PeriodicalIF":4.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on \"Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver disease\".","authors":"Cunkai Wang, Pingping Li, Yun Bai","doi":"10.1016/j.aohep.2025.102129","DOIUrl":"10.1016/j.aohep.2025.102129","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102129"},"PeriodicalIF":4.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145172286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on \"Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study\".","authors":"Qing Chen, Meng Meng, Chunhui Yuan","doi":"10.1016/j.aohep.2025.102127","DOIUrl":"10.1016/j.aohep.2025.102127","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102127"},"PeriodicalIF":4.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145172319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tomáš Uher, Pavlína Kleinová, Jana Woronyczová, Lubomír Štěpánek, Manuela Vaněčková, Jan Krásenský, Renata Cífková, Dana Horáková, Eva Havrdová, David Hoskovec, Martin Leníček, Libor Vítek
{"title":"Serum bilirubin concentrations and their association with clinical and radiological outcomes in multiple sclerosis: A large cohort study.","authors":"Tomáš Uher, Pavlína Kleinová, Jana Woronyczová, Lubomír Štěpánek, Manuela Vaněčková, Jan Krásenský, Renata Cífková, Dana Horáková, Eva Havrdová, David Hoskovec, Martin Leníček, Libor Vítek","doi":"10.1016/j.aohep.2025.102117","DOIUrl":"10.1016/j.aohep.2025.102117","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Bilirubin is negatively associated with neurodegenerative diseases, including multiple sclerosis (MS). Since previous studies were small or did not evaluate all diagnostic aspects, the objective of the present study was to assess a large cohort of MS patients with multiple determinations of serum bilirubin.</p><p><strong>Patients and methods: </strong>The study was carried out in 2,696 consecutive MS patients (median age=37.1 years, disease duration=6.8 years, follow-up duration=7.2 years, and Expanded Disability Status Scale (EDSS)=2.5) with 28,501 visits. Individuals from the Czech post-MONICA study representing the general Czech population (n=2,621) were used as controls. Serum bilirubin concentrations in study subjects were compared with multiple diagnostic and clinical parameters.</p><p><strong>Results: </strong>Serum bilirubin concentrations in MS patients were significantly lower compared to the general population (8.3 vs. 9.6 μmol/L, P<0.001). Hyperbilirubinemia >17 µmol/L in MS patients was much less frequent compared to the general population (8.2 vs. 12.5 %, P<0.001). An increase in disease duration by 10 years was associated with an 8 % decrease in bilirubin concentration (p<0.0001). Ten percent higher serum bilirubin concentration was associated with a 9 % decrease in EDSS (p=0.001) and a 1.5 % decrease in normalized brain volume (p<0.0001). The frequencies of individual UGT1A1 (TA)n/n genotypes did not differ between MS patients and the control population.</p><p><strong>Conclusions: </strong>MS patients have markedly lower serum bilirubin concentrations, most likely due to consumption during the increased oxidative stress since the frequencies of UGT1A1 were comparable in the MS and control populations. Higher serum bilirubin is associated with lower disability and lower brain atrophy.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102117"},"PeriodicalIF":4.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George
{"title":"Drug pricing for hepatitis B and C in Australia and Japan.","authors":"Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George","doi":"10.1016/j.aohep.2025.102118","DOIUrl":"10.1016/j.aohep.2025.102118","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102118"},"PeriodicalIF":4.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diagnosis of metabolic dysfunction-associated steatotic liver disease by triglyceride glucose-body mass index: A systematic review and meta-analysis.","authors":"Kexin Du, Yafang Huang, Yanhui Yu, Jianrong Guo, Jianmei Feng, Feng Jiang","doi":"10.1016/j.aohep.2025.102122","DOIUrl":"10.1016/j.aohep.2025.102122","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly common globally, but current diagnostic methods are inaccessible. This study aims to evaluate the efficacy of triglyceride glucose-body mass index (TyG-BMI) as a noninvasive diagnostic tool for MASLD.</p><p><strong>Materials and methods: </strong>Embase, PubMed, Cochrane Library, and Web of Science up to July 2025 were searched for related studies. Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 was utilized for quality assessment. The effect size, odds ratio (OR), specificity, sensitivity, positive/negative likelihood ratios, diagnostic odds ratio, and heterogeneity were pooled using Stata18.0 and Meta-Disc1.4. The summary receiver operating characteristic (SROC) curves were plotted and the area under the curve (AUC) values were calculated. Random- or fixed-effects models were adopted based on the results of the heterogeneity test. Moreover, we investigated the source and influence of heterogeneity by subgroup and sensitivity analyses, and examined publication bias.</p><p><strong>Results: </strong>Twenty-nine studies were included. The meta-analysis revealed a higher TyG-BMI in MASLD patients than in non-MASLD patients (SMD 3.09, 95 % CI 2.49-3.68, P < 0.001). For each one-unit increase in TyG-BMI, the MASLD risk rose by 5 % (OR 1.05, 95 % CI 1.04-1.07, P < 0.001). The pooled sensitivity, specificity, and AUC of the diagnostic efficacy of TyG-BMI were 0.81 (95 % CI 0.77-0.85), 0.72 (95 % CI 0.67-0.77), and 0.83 (95 % CI 0.80-0.86), respectively. The stratified analysis by sex revealed that the diagnostic efficacy was superior in females (sensitivity: 0.82, specificity: 0.80).</p><p><strong>Conclusions: </strong>TyG-BMI, a cost-efficient and convenient indicator, is favorable for diagnosing MASLD, especially in females, which is worth popularizing.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102122"},"PeriodicalIF":4.4,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland France.","authors":"Alolia Aboikoni, Manon Allaire, Dominique Louvel, Marthe Alogo A Nwatsok, Paul Ngock Dime, Ala Ouni, Larissa Tangan, Magaly Zappa, Kinan Drak Alsibai, Maylis Douine, Mathieu Nacher, Lucie Catherine, Cecilia Busso, Nathalie Ganne, Moana Gelu-Simeon","doi":"10.1016/j.aohep.2025.102120","DOIUrl":"10.1016/j.aohep.2025.102120","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Limited data are available on the prognosis of hepatocellular carcinoma (HCC) in the French overseas territories (FOT). This study aimed to describe the characteristics and outcomes of patients diagnosed with HCC in FOT, comparing them to those from a tertiary center located in Île-de-France (IDF).</p><p><strong>Materials and methods: </strong>We retrospectively included all patients with HCC diagnosis between 2013 and 2023 in the FOT and IDF. Socio-demographic and medical data were collected, with the first treatment performed and survival data. Overall survival was analyzed using Kaplan- Meier methods and Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 1114 patients were included (FOT 11%, IDF 89%). FOT patients had higher rates of hepatitis B (36% vs. 16%, p<0.001) and worse liver function (defined by higher MELD scores and fewer Child A cases) at HCC diagnosis. In contrast, IDF patients had a higher prevalence of MASLD (29% vs. 16%, p=0.004). HCC was diagnosed at more advanced stages in FOT compared to IDF, with 71% vs. 49% (p<0.001) of cases outside Milan criteria and 29% vs. 5% (p<0.001) in BCLC-D, leading to a significantly lower survival in FOT (median 9 vs. 23 months, p=0.02).</p><p><strong>Conclusions: </strong>HCC patients in FOT have a poorer prognosis compared to IDF, with diagnoses at more advanced stages, limiting curative treatment options. These findings highlight the need for improved access to care and screening strategies for earlier diagnosis of HCC in FOT.</p>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":" ","pages":"102120"},"PeriodicalIF":4.4,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}